Wedbush Equities Analysts Reduce Earnings Estimates for VYGR

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at Wedbush decreased their Q1 2025 EPS estimates for Voyager Therapeutics in a research report issued on Wednesday, March 12th. Wedbush analyst Y. Zhong now expects that the company will earn ($0.37) per share for the quarter, down from their prior estimate of ($0.27). Wedbush currently has a “Outperform” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($0.88) EPS and FY2029 earnings at ($0.87) EPS.

Several other equities analysts have also weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday. Citigroup initiated coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. Finally, Canaccord Genuity Group cut their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Trading Down 4.2 %

Shares of NASDAQ:VYGR opened at $3.90 on Monday. Voyager Therapeutics has a 1-year low of $3.56 and a 1-year high of $10.66. The stock has a market capitalization of $213.04 million, a P/E ratio of 5.49 and a beta of 0.99. The business has a 50-day moving average price of $4.83 and a two-hundred day moving average price of $5.82.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The firm had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the business posted $1.25 earnings per share.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics during the 4th quarter worth about $29,000. Tower Research Capital LLC TRC raised its holdings in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management boosted its position in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the last quarter. Oxford Asset Management LLP bought a new position in Voyager Therapeutics in the fourth quarter valued at approximately $60,000. Finally, Intech Investment Management LLC acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth approximately $74,000. Institutional investors own 48.03% of the company’s stock.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.